Abstract 3547
Background
With the increased use of ICIs among cancer patients, there is growing interest in understanding the outcome and management of irAEs. This study addressed this knowledge gap by examining the real-world outcomes in patients experiencing irAEs.
Methods
An observational study was conducted using the Premier Healthcare Database, a US national hospital discharge database (Mar 2015-Dec 2017). Twenty-eight distinct types of irAEs per the ASCO practice guidelines were identified. Patients with ICD-9/10 codes for NSCLC, RCC, UC, or MCC and one of 28 irAEs during the study period were included. Index irAE visits were defined as the first visit with a confirmed ICI usage during a 90-day look-back period from the first irAE. Patients were then followed for 90 days post-irAE to determine irAE-related inpatient admissions, all-cause in-hospital mortality, and ICI re-initiation.
Results
15,277 distinct irAEs occurred across 13,030 patients, with 5,732 (38%) of irAE events with an inpatient index visit. Among the 6590 patients having ≥1 irAEs, 44% had 1 irAE of any type, 25% had 2, 14% had 3, and 17% had ≥4 irAEs. Among the 28 types of irAEs, inpatient index visits were most common for myocarditis, transverse myelitis, and toxic epidermal necrolysis (all 100%), and least common for acquired hemophilia (0%), polymyalgia-like syndrome (10%), and adrenal insufficiency (10%). During the follow-up period, patients with inpatient index admissions had higher (p < 0.001) subsequent inpatient admissions and higher mortality, and lower (p < 0.001) ICI re-initiation (Table).Table:
1284P
Index Visit Type | |||
---|---|---|---|
Clinical outcome: 90 days following index irAE | All | Inpatient | Outpatient |
irAE-related inpatient admission | 23% | 26%* | 19%* |
No ICI re-initiation | 47% | 70%** | 28%** |
All-cause inpatient mortality | 12% | 23%*** | 6%*** |
p < 0.001,
**p < 0.001,
***p < 0.001
Conclusions
Approximately half of patients receiving an ICI experienced an irAE that required clinical management in inpatient or outpatient setting. Occurrence of irAEs was associated with treatment discontinuation. Overall, irAE cases with inpatient index visits tended to have poor outcomes and required more follow-up management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
EMD Serono, Inc.
Funding
This study was sponsored by EMD Serono, Inc, a business of Merck Healthcare KGaA, Darmstadt, Germany, and is part of an alliance between EMD Serono/Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY, USA.
Disclosure
S. George: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Research grant / Funding (institution): Novartis; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Corvus; Advisory / Consultancy: Genentech; Advisory / Consultancy: Sanofi/Genzyme; Advisory / Consultancy, Research grant / Funding (institution): Pfizer, Inc; Research grant / Funding (institution): Acceleron; Research grant / Funding (institution): Merck ; Research grant / Funding (institution): Agensys; Research grant / Funding (institution): Eisai; Advisory / Consultancy: EMD Serono, Inc. Y. Zheng: Full / Part-time employment, current employment (self): EMD Serono, Inc; Full / Part-time employment, previous employment (self) : Janssen; Licensing / Royalties, Full / Part-time employment, spouse and immediate family: Shire (now Takeda); Full / Part-time employment, spouse: Eli Lilly. R. Kim: Full / Part-time employment: Pfizer, Inc.; Shareholder / Stockholder / Stock options: Exelixis. T. Yu: Full / Part-time employment: EMD Serono, Inc. J. Dreyfus: Shareholder / Stockholder / Stock options, Full / Part-time employment: Premier, Inc. J.A. Gayle: Full / Part-time employment: Premier, Inc. C. Wassel: Full / Part-time employment: Premier, Inc. H. Phatak: Full / Part-time employment: EMD Serono, Inc.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract